Welcome to our dedicated page for Vaxart SEC filings (Ticker: VXRT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Vaxart, Inc. filings document a clinical-stage biotechnology issuer focused on oral recombinant pill vaccines and a common stock quoted on the OTCQX Best Market under the symbol VXRT. The company’s regulatory record includes financial-result 8-K reports, registration statements and registration-rights disclosures tied to common stock financing, and exhibits covering material agreements.
The filings also cover board appointments and independence determinations, lease terminations and facility changes, capital structure items, revenue categories such as government contract and collaboration revenue, and formal market-status records, including a Form 25 for removal of the common stock from Nasdaq listing and registration.
Vaxart, Inc. (VXRT) has had its common stock removed from listing and/or registration on the Nasdaq Stock Market LLC. Nasdaq filed Form 25 under Section 12(b) of the Securities Exchange Act of 1934, stating that it has complied with its rules to strike this class of securities from listing and withdraw its registration on the exchange. The filing specifies that the action concerns Vaxart’s common stock, which means the shares will no longer be listed for trading on Nasdaq.
Vaxart, Inc. (VXRT) reported an insider share purchase by a director. On 11/17/2025, the director bought 23,217 shares of common stock in an open-market transaction at $0.393 per share and a further 16,783 shares at $0.405 per share. After these purchases, the director beneficially owned 96,566 shares, held directly. The filing notes the person’s role as a director and confirms the report is filed by a single reporting person.
Vaxart, Inc. reported third‑quarter results highlighting a sharp rise in government contract revenue and a strengthened liquidity outlook. Revenue reached $72.4 million for the quarter, driven by HHS BARDA contracts tied to the ATI‑RRPV program, while operating expenses were $80.2 million, resulting in an operating loss of $7.8 million and a net loss of $8.1 million (basic and diluted loss per share of $0.04).
Cash, cash equivalents and short‑term investments totaled $28.8 million as of September 30, 2025. The balance sheet reflects $42.7 million in accounts receivable and $43.2 million in unbilled receivables from government contracts, alongside $64.8 million in deferred government revenue. Vaxart recognized $71.8 million of cost‑plus‑fixed‑fee revenue in Q3 under the 2024 ATI‑RRPV Contract.
After quarter‑end, Vaxart entered an exclusive license and collaboration with Dynavax, including a $25.0 million upfront fee and a $5.0 million equity purchase at $0.45 per share, providing approximately $30.0 million in total proceeds. Management reports these actions extend cash runway into the second quarter of 2027. Shares outstanding were 240,069,844 as of November 6, 2025.
Vaxart, Inc. (VXRT) furnished an 8-K to announce it issued a press release with a business update and financial results for the quarter ended September 30, 2025. The company attached the release as Exhibit 99.1 and stated the information is being furnished, not filed, under the Exchange Act and Securities Act provisions.
Vaxart also noted its common stock trades exclusively on the OTCQX Best Market under the symbol VXRT. No specific financial figures are included in this report; details are contained in the press release referenced as Exhibit 99.1.
Vaxart, Inc. is offering and selling 11,111,111 shares of common stock at $0.45 per share in a privately negotiated transaction with Dynavax Technologies Corporation.
The company estimates net proceeds of approximately $5 million, to be used for general corporate purposes, including working capital, operating expenses, and capital expenditures. No underwriters or placement agents are involved. Delivery of shares is expected on or about November 6, 2025. Shares outstanding were 228,957,259 as of September 30, 2025, and are expected to be 240,069,844 immediately after the offering. Vaxart’s stock trades on the OTCQX under VXRT; the last reported price on November 3, 2025 was $0.33 per share.
Vaxart (VXRT) signed an exclusive, worldwide license and collaboration with Dynavax for its investigational oral coronavirus vaccines, including its oral COVID‑19 candidate. Vaxart will complete its ongoing Phase 2b trial and an end‑of‑Phase 2 FDA meeting; after that, Dynavax may elect to assume further development.
Dynavax will pay $25 million upfront and purchase 11,111,111 Vaxart shares at $0.45 per share (about $5 million) under Vaxart’s shelf registration, with closing expected on or about November 6, 2025. If Dynavax elects to take over development, it will pay an additional $50 million.
Vaxart may receive up to $195 million in regulatory milestones, up to $425 million in net sales milestones, and tiered royalties in the low‑to‑mid teens on net sales for licensed indications. Vaxart retains its platform rights for all non‑coronavirus indications. If Dynavax does not elect to continue, the agreement will terminate.
On October 8, 2025, Vaxart, Inc. disclosed that BARDA (through ATI) issued a Follow-Up Notice narrowing the scope of a Project Agreement to exclude "Paused Work." The company said ongoing activities will continue for the approximately 5,000 participants already enrolled in the Trial and that Vaxart will continue to receive funding to evaluate those participants. Vaxart stated it believes the Trial data from enrolled participants could provide useful insights and a foundation of evidence to potentially advance its COVID program. The filing clarifies these changes are furnished and not "filed" under Section 18, and it includes standard forward-looking statement language about risks and uncertainties.
Vaxart, Inc. reports that Nasdaq has decided to delist its securities after the company failed to meet conditions previously set by a Nasdaq Hearings Panel. Those conditions required shareholder approval of a reverse stock split by September 5, 2025, completion of the reverse split by October 6, 2025, and proof that the company met Nasdaq’s minimum bid price requirement. Vaxart withdrew its reverse stock split proposal on September 18, 2025, which left these conditions unmet.
Nasdaq’s Office of the General Counsel sent a letter on September 19, 2025 stating that Vaxart’s securities will be delisted. Trading of Vaxart’s common stock on Nasdaq has already been suspended since the open of trading on July 8, 2025. The company’s common stock is currently quoted on the OTCQX® Best Market under the symbol VXRT, meaning its shares continue to trade but no longer on a national securities exchange.
Vaxart, Inc. informed investors that a previously adjourned special meeting of stockholders, originally convened on September 5, 2025 and reconvened for September 19, 2025, will not be reconvened because the company withdrew the listed proposal from stockholder consideration on September 18, 2025. The proposal had been included in a proxy statement filed on August 6, 2025 and the meeting was adjourned earlier to give stockholders additional time to vote. The filing states only the withdrawal decision and that the company will not reconvene the adjourned meeting; no additional rationale, future steps, or timing for any alternative actions were provided.
Vaxart, Inc. faces an organized shareholder opposition: a group calling itself the Concerned Vaxart Stockholders issued an exempt solicitation press release dated September 18, 2025 urging holders to vote AGAINST the proposed reverse stock split.
The group notes the reverse split was overwhelmingly rejected at the June 13, 2025 annual meeting (twice adjourned) and cites the originally scheduled September 5, 2025 special meeting as further evidence of shareholder resistance. The petitioners criticize recent board actions and request constructive dialogue and governance reforms rather than symbolic appointments.